Literature DB >> 10563710

Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations.

N Christeff1, J C Melchior, P de Truchis, C Perronne, E A Nunez, M L Gougeon.   

Abstract

BACKGROUND: A syndrome of lipodystrophy, associated with hypertriglyceridaemia, hypercholesterolaemia, hyperinsulinaemia and peripheral insulin resistance has been reported in protease inhibitor (PI)-treated HIV-infected patients. Because lipid metabolism, fat mass distribution and insulin resistance are partly regulated by steroid hormones, we questioned whether lipodystrophy is related to hormonal perturbations.
OBJECTIVE: To evaluate serum lipid and steroid hormone concentrations in HIV-positive men on highly active antiretroviral therapy (HAART) in order to determine whether dyslipidaemia, peripheral loss of fatty tissue and central fat accumulation are related to steroid hormone modifications.
DESIGN: A cross-sectional study.
METHODS: Thirty-seven HIV-1-positive men on HAART, 23 of whom had symptoms of lipodystrophy, according to a subjective clinical score of lipodystrophy (SCSL), were tested. Serum concentrations of cholesterol, triglycerides and their subclasses, apolipoproteins and steroid hormones, including cortisol, dehydroepiandrosterone (DHEA), DHEA sulphate, androstenedione, testosterone and dihydrotestosterone were measured.
RESULTS: Serum cholesterol, very low density lipoprotein (VLDL) cholesterol, triglycerides, VLDL triglycerides, high density lipoprotein (HDL) and low density lipoprotein (LDL) triglycerides, apolipoprotein B (ApoB) and atherogenic ratios of cholesterol:HDL cholesterol, LDL cholesterol:HDL cholesterol and ApoB:apolipoprotein A1 (ApoA1) were significantly increased in lipodystrophy-positive compared with lipodystrophy-negative men. The serum cortisol level was similar in lipodystrophy-positive versus lipodystrophy-negative men, but was elevated compared with controls. Serum DHEA was significantly lower in lipodystrophy-positive versus lipodystrophy-negative men and, consequently, the cortisol:DHEA ratio was increased in lipodystrophy-positive patients. A positive correlation was found between the cortisol:DHEA ratio and increased levels of atherogenic lipids. In addition, the SCSL was positively correlated with dyslipidaemia and the cortisol:DHEA ratio.
CONCLUSION: This study demonstrates an association between the cortisol:DHEA ratio, lipid alterations and lipodystrophy. This syndrome might result from an imbalance between peripheral lipolysis and lipogenesis, both regulated by cortisol and DHEA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10563710     DOI: 10.1097/00002030-199911120-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

Review 1.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

2.  Fat distribution in men with HIV infection.

Authors:  Peter Bacchetti; Barbara Gripshover; Carl Grunfeld; Steven Heymsfield; Heather McCreath; Dennis Osmond; Michael Saag; Rebecca Scherzer; Michael Shlipak; Phyllis Tien
Journal:  J Acquir Immune Defic Syndr       Date:  2005-10-01       Impact factor: 3.731

3.  Fat distribution in women with HIV infection.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2006-08-15       Impact factor: 3.731

4.  Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.

Authors:  M Shahmanesh; H Jaleel; Y DeSilva; J D Ross; M Caslake; R Cramb
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

5.  High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.

Authors:  Jean-Marc Tréluyer; Jean-Pierre Morini; Jérome Dimet; Isabelle Gorin; Elisabeth Rey; Jean Deleuze; Pierre-François Ceccaldi; Jean-Paul Escande; Gérard Pons; Nicolas Dupin
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 6.  HIV disease and advanced age: an increasing therapeutic challenge.

Authors:  Roberto Manfredi
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Leptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic Implications.

Authors:  Sotirios Tsiodras; Christos Mantzoros
Journal:  Am J Infect Dis       Date:  2006

8.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

Review 9.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.

Authors:  David Wohl; Rebecca Scherzer; Steven Heymsfield; Michael Simberkoff; Stephen Sidney; Peter Bacchetti; Carl Grunfeld
Journal:  J Acquir Immune Defic Syndr       Date:  2008-05-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.